Skip to Content

Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment.
NBTXR3 – Nanobiotix’s novel, first-in-class lead product candidate aims to expand the benefits of radiotherapy for millions of cancer patients. NBTXR3 is being evaluated both as a single agent activated by radiotherapy alone, and as a combination product with other anti-cancer therapies including chemotherapy and immune checkpoint inhibitors.
NBTXR3 – Nanobiotix’s novel, first-in-class lead product candidate aims to expand the benefits of radiotherapy for millions of cancer patients. NBTXR3 is being evaluated both as a single agent activated by radiotherapy alone, and as a combination product with other anti-cancer therapies including chemotherapy and immune checkpoint inhibitors.